SNT 2.22% 4.4¢ syntara limited

Ann: Pharmaxis Acquires Control, Increases Stake in LOXL2 Program, page-6

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 7,135 Posts.
    lightbulb Created with Sketch. 546
    1. Interest of LOXL2 from Pharmas are intensified.
    2. Synairgen has near-term cash problem, and happy to sacrifice long term potential in LOXL2 for badly needed cash, which PXS happen to have in the bank.

    Early-mid 2018 will be interesting for PXS, when multiple trails approaching the results.
    Last edited by newB: 24/12/17
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.